Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

NCT03767725 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma in Relapse

Interventions

BIOLOGICAL: Treatment

Sponsor

Shenzhen Second People's Hospital